Caution when using 1,3, β-D-glucan in the CSF as a biomarker of <i>Candida albicans</i> meningitis

Barbolini, Laura; Riat, Arnaud; Van Delden, Christian; Schrenzel, Jacques

doi:10.1016/j.ijid.2022.06.033

Scientific article

English

Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis

ContributorsBarbolini, Laura; Riat, Arnaud

; Van Delden, Christian; Schrenzel, Jacques

Published inInternational journal of infectious diseases, vol. 122, p. 531-533

Publication date2022-09

First online date2022-06-26

Abstract

Relying on a biomarker to diagnose or follow up the treatment of a Candida albicans meningitis would have an impact on patient management. The biomarker 1,3, β-D-glucan (BDG), developed for serum testing, shows inconsistent values when applied on cerebrospinal fluid (CSF), and its use with the current protocol on CSF samples warrants caution.

Keywords

Biomarkers
Candida albicans
Humans
Meningitis
Proteoglycans
Beta-Glucans

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Citation (ISO format)

BARBOLINI, Laura et al. Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis. In: International journal of infectious diseases, 2022, vol. 122, p. 531–533. doi: 10.1016/j.ijid.2022.06.033

Article (Published version)

CC BY-4.0

Identifiers

PID : unige:168960
DOI : 10.1016/j.ijid.2022.06.033
PMID : 35760379

Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S1201971222003691

Journal ISSN1201-9712

95views

747downloads

Creation05/01/2023 14:38:58

First validation22/05/2023 15:43:30

Update13/01/2025 13:27:49

Status update13/01/2025 13:27:49

Last indexation13/01/2025 13:38:04

Archive ouverte UNIGE

Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis

Technical informations